Person:
ERGENÇ, MUHAMMER

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

ERGENÇ

First Name

MUHAMMER

Name

Filters

2021 - 20245
Reset filters

Settings

Author: YEGEN, ŞEVKET CUMHUR × Start date: 2020 ×

Search Results

Now showing 1 - 5 of 5
  • No Thumbnail Available
    PublicationMetadata only
    Enhanced recovery after pancreatic surgery: A prospective randomized controlled clinical trial
    (WILEY, 2021) ERGENÇ, MUHAMMER; Ergenc, Muhammer; Karpuz, Sakir; Ergenc, Merve; Yegen, Cumhur
    Background and Objectives The enhanced recovery after surgery (ERAS) protocol is a perioperative care bundle designed to achieve early healing after surgical procedures. This study aims to investigate the effect of the ERAS protocol on postoperative complications, length of hospital stay (LOS), and readmission rates in pancreatic surgery patients. Methods The study was designed as a prospective and randomized controlled study between January 2016 and November 2018 on pancreatic surgery patients. A total of 38 patients were analyzed, 18 of whom were in the ERAS group and 20 in the control group. Patient demographics, intraoperative variables, and postoperative outcomes were recorded. Results The groups were similar regarding age, sex, surgery type, American Society of Anesthesiologists scores, and laboratory results. There was no significant difference in the intraoperative variables. Early oral feeding was preferred, mostly in the ERAS group compared to the control group. Perioperative complication rates, including delayed gastric emptying and pancreatic fistula, LOS, and readmission rates, were similar between the two groups. Conclusions The ERAS protocol provided a minimal decrease in the total complication rates and had no effect on severe complications. Therefore, the ERAS protocol seems feasible and can be applied safely in pancreatic surgery patients.
  • Thumbnail Image
    PublicationOpen Access
    Prognostic significance of metastatic lymph node ratio in gastric cancer: a Western-center analysis
    (2023-08-01) UPRAK, TEVFİK KIVILCIM; AKIN, MUHAMMED İKBAL; ÇELİKEL, ÇİĞDEM; YEGEN, ŞEVKET CUMHUR; ERGENÇ, MUHAMMER; Ergenç M., Uprak T. K., Akın M. İ., Hekimoğlu E. E., Çelikel Ç., Yegen Ş. C.
    BackgroundTumor-node-metastasis (TNM) staging is the central gastric cancer (GC) staging system, but it has some disadvantages. However, the lymph node ratio (LNR) can be used regardless of the type of lymphadenectomy and is considered an important prognostic factor. This study aimed to evaluate the relationship between LNR and survival in patients who underwent curative GC surgery.MethodsAll patients who underwent radical gastric surgery between January 2014 and June 2022 were retrospectively evaluated. Clinicopathological features of tumors, TNM stage, and survival rates were analyzed. LNR was defined as the ratio between metastatic lymph nodes and total lymph nodes removed. The LNR groups were classified as follows: LNR0 = 0, 0.01 < LNR1 ≤ 0.1, 0.1 < LNR2 ≤ 0.25 and LNR3 > 0.25. Tumor characteristics and overall survival (OS) of the patients were compared between LNR groups.ResultsAfter exclusion, 333 patients were analyzed. The mean age was 62 ± 14years. According to the LNR classification, no difference was found between groups regarding age and sex. However, TNM stage III disease was significantly more common in LNR3 patients. Most patients (43.2%,n = 144) were in the LNR3 group. In terms of tumor characteristics (lymphatic, vascular, and perineural invasion), the LNR3 group had significantly poorer prognostic factors. The Cox regression model defined LNR3, TNM stage II—III disease, and advanced age as independent risk factors for survival. Patients with LNR3 demonstrated the lowest 5-year OS rate (35.7%) (estimated mean survival was 30 ± 1.9months) compared to LNR 0–1–2.ConclusionOur study showed that a high LNR was significantly associated with poor OS in patients who underwent curative gastrectomy. LNR can be used as an independent prognostic predictor in GC patients.
  • Thumbnail Image
    PublicationOpen Access
    Outcomes of proximal versus total gastrectomy for proximal gastric cancer: A propensity score-matched analysis of a western center experience
    (2023-01-01) UPRAK, TEVFİK KIVILCIM; ERGENÇ, MUHAMMER; AKMERCAN, AHMET; YEGEN, ŞEVKET CUMHUR; UPRAK T. K., ERGENÇ M., AKMERCAN A., YEGEN Ş. C.
    Purpose: In this western study, we aimed to compare perioperative outcomes, postoperative complications, and overall survival in patients who underwent total gastrectomy (TG) or proximal gastrectomy (PG) for proximal gastric cancer (GC). Methods: Patients who underwent GC surgery at Marmara University Hospital between January 2014 and December 2021 were evaluated retrospectively. Propensity score matching (PSM) was performed to balance the baseline characteristics of patients undergoing PG and TG. Data on patients’ demographics, clinicopathological features of tumors, complications, and survival rates were analyzed. Perioperative outcomes and overall survival of the patients were compared between PG and TG groups. Results: A total of 212 patients were included in this study, with 53 patients in the PG and 159 in the TG group. After 1:1 matching according to PSM, 46 patients in the PG group were matched to 46 in the TG group. After PSM, there were no differences in clinicopathological outcomes except retrieved lymph nodes. In terms of short-term outcomes, overall perioperative morbidity (Clavien Dindo ≥ 3a) was significantly higher in the PG group (p = 0.01). However, there was no significant difference when the complications were considered separately. In the long-term follow-up, reflux esophagitis was associated with the PG group (p=0.04). In multivariate analysis, positive surgical margin and lymphovascular invasion were significant factors related to overall survival. Overall, 5-year survival was 55% in matched patients. The difference in survival was not statistically significant (57 vs. 69 months, p = 0.3) between the two groups. Conclusions: Proximal gastrectomy is applicable to patients up to stage 3 disease, with no difference in overall survival, with caution in early complications and reflux esophagitis. Among all demographic and oncological factors, lymphovascular invasion and resection margin were significantly associated with worse survival.
  • No Thumbnail Available
    PublicationMetadata only
    Pankreas cerrahisi yapılan hastalarda eras uygulamasının etkisi
    (2021-06-14) ERGENÇ, MUHAMMER; KARPUZ, ŞAKİR; YEGEN, ŞEVKET CUMHUR; Ergenç M., Karpuz Ş., Ergenç E. M., Yegen Ş. C.
    Amaç:Cerrahi sonrası hızlandırılmış iyileşme (ERAS: Enhanced Recovery After Surgery) hastaya detaylı eğitim verilerek ve hasta güvenliği gözetilerek uygulanan, perioperatif dönemde intravenöz hidrasyonun kısıtlanması, postoperatif erken oral rejim başlanarak sıvı ihtiyacını bu yolla giderilmesi, daha etkin analjezi sağlanması, yerleştirilen drenlerin daha erken çekilmesi ve hastanın erken mobilize edilmesi esasına dayanan bir protokoldür. Son dekadda tanımlanan bu protokol ile elektif cerrahiler sonrası hastanede yatış sürelerinin kısaltılması ve ilişkili komplikasyonların azaltılması hedeflenmiştir. Bu çalışmada ERAS protokolünün pankreas cerrahisi hastalarında postoperatif komplikasyonlar, yatış süresi, tekrarlayan hastane yatışı ve reoperasyon oranlarına etkisinin araştırılması hedeflenmiştir.Gereç ve Yöntem:Çalışma Ocak 2016 ile Kasım 2018 tarihleri arasında Marmara Üniversitesi Pendik Eğitim Araştırma Hastanesi Genel Cerrahi Kliniği’nde laparotomi ile elektif pankreas kanseri cerrahisi geçiren hastalar üzerinde prospektif olarak yapılmış olup hastalar standart bakım ve ERAS protokolü esasına göre iki gruba randomize edildi. Hastaların demografik verileri, laboratuvar tetkik sonuçları ile birlikte perioperatif verilen sıvı miktarı, kanama ve transfüzyon durumu kaydedildi. Postoperatif sonda çekilme günleri, ağrı ve gelişen komplikasyonlar ve taburculuk günleri takip edilerek kaydedildi.İstatistiksel analizde sayısal değerler için nonparametrik t testi, kategorik değerler için ki kare kullanıldı.Bulgular:On sekizi ERAS protokolü, 20’si standar t bakım protokolü olmak üzere toplam 38 hastanın verileri istatiksel analize dahil edildi. Gruplar yaş cinsiyet, laboratuvar değerleri, cerrahi tipi ve ASA skorları açısından benzer dağılmaktaydı. Ameliyat süresi, ameliyatta verilen iv sıvı ve transfüzyon açısından fark saptanmadı. Kanama miktarı ERAS grubunda median değer 300 ml (100-550) iken, kontrol grubunda 500 ml (200-750) bulundu. Postoperatif takipte; günlük verilen iv sıvı ortalaması, nazogastrik çekilme günü, postoperatif vizüel analog skala skoru değerleri, mobilizasyon, postop gaz çıkışı ve defekasyon yönünden ERAS ve kontrol grubu arasında fark yoktu. ERAS gurunda tüm hastalara epidural analjezi uygulanırken kontrol grubunda uygulanmadı. ERAS grubunda 17 (%94) hastaya erken beslenme uygulanırken bu oran kontrol grubunda 11 (%55) idi. En sık gelişen komplikasyonlar olan gecikmiş mide boşalması ve pankreatik fistül dahil olmak üzere postoperatif komplikasyon açısından iki grup arasında fark izlenmedi. Çalışmanın primer çıkarımı olan hastanede kalma süresi ve yeniden yatış açısından ERAS ve kontrol grubu arasında anlamlı fark izlenmedi.Sonuç:Sunulan çalışmada ERAS uygulamalarının total komplikasyon oranını azalttığı, özellikle abdominal enfeksiyon, hastane yatış süresi, mide boşalma güçlüğü gibi hafif olanları etkilerken, pankreas fistülü, reoperasyon, tekrar yatış ve mortalite gibi ağır olanlar üzerine etkisi olmadığı ortaya konulmuştur. Bu uygulamaların başlatılması pankreas cerrahisi için güvenlik tehdidi oluşturmamaktadır.Anahtar kelimeler:Pankreas cerrahisi, Cerrahi sonrası hızlandırılmış iyileşme, ERAS
  • Thumbnail Image
    PublicationOpen Access
    Pancreaticoduodenectomy in patients < 75 years versus ≥ 75 years old: a comparative study
    (2024-12-01) ERGENÇ, MUHAMMER; UPRAK, TEVFİK KIVILCIM; KARPUZ, ŞAKİR; COŞKUN, MÜMİN; YEGEN, ŞEVKET CUMHUR; ATICI, ALİ EMRE; ERGENÇ M., UPRAK T. K., Özocak A. B., KARPUZ Ş., COŞKUN M., YEGEN Ş. C., ATICI A. E.
    Objective: This study aimed to compare the postoperative outcomes of < 75-year-old patients and ≥ 75-year-old patients who underwent pancreaticoduodenectomy (PD) for pancreatic head and periampullary region tumors. Methods: Patients who underwent PD in our hospital between February 2019 and December 2023 were evaluated. Demographics, Eastern Cooperative Oncology Group Performance Status (ECOG-PS) scores, American Society of Anesthesiologists (ASA) scores, comorbidities, hospital stays, complications, and clinicopathological features were analyzed. Patients were divided into < 75 years (Group A) and ≥ 75 years (Group B) groups and compared. Results: The median age of the entire cohort (n = 155) was 66 years (IQR = 16). There was a significant difference between Group A (n = 128) and Group B (n = 27) regarding the ECOG-PS and ASA scores. There was no significant difference between the groups regarding postoperative complications. The 30-day mortality rate was greater in Group B (p = 0.017). Group B had a cumulative median survival of 10 months, whereas Group A had a median survival of 28 months, with a statistically significant difference (p < 0.001). When age groups were stratified according to ECOG-PS, for ECOG-PS 2–3 Group A, survival was 15 months; for ECOG-PS 2–3 Group B, survival was eight months, and the difference was not statistically significant (p = 0.628). Conclusions: With the increasing aging population, patient selection for PD should not be based solely on age. This study demonstrated that PD is safe for patients older than 75 years. In older patients, performance status and the optimization of comorbidities should be considered when deciding on a candidate’s suitability for surgery.